^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR L643V |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Lung adenocarcinoma organoids harboring EGFR 19Del and L643V double mutations respond to osimertinib and gefitinib
Published date:
03/19/2021
Excerpt:
An EGFR double mutation 19Del/L643V was detected in the sequence of patient's cancer specimen....The drug sensitivity test showed that the cancer organoids that retained original mutations were sensitive to anticancer agents osimertinib and gefitinib, while resistant to erlotinib and icotinib....The uncommon EGFR double mutation exhibits distinctive sensitivities towards different target drugs of EGFR-TKIs.
DOI:
10.1097/MD.0000000000024793
